Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia - Related Studies

Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

This study is ongoing, but not recruiting participants.

Study NCT00096044. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia

2	Additional conditions recognized in this trial
		Leukemia, B-Cell
		Leukemia, Lymphocytic, Chronic, B-Cell
		Leukemia, Lymphoid

3	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Interventions listed in this trial
		lenalidomide
		rituximab

5	More general drug interventions related to this trial
		Antineoplastic Agents
		Antirheumatic Agents
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		Roswell Park Cancer Institute